Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;23(2):73–82. doi: 10.1002/clc.4960230203

Amiodarone: What have we learned from clinical trials?

Gerald V Naccarelli 1,✉, Deborah L Wolbrette 1, Joseph T Dell'Orfano 1, Hemantkumar M Patel 1, Jerry C Luck 1
PMCID: PMC6655150  PMID: 10676597

Abstract

Amiodarone is an antiarrhythmic agent commonly used in the treatment of supraventricular and ventricular tachyarrhythmias. This paper reviews clinical trials in which amiodarone was used in one of the treatment arms. Key post‐myocardial infarction trials include EMIAT and CAMIAT, both of which demonstrated that amiodarone reduced arrhythmic but not overall mortality. In patients with congestive heart failure (CHF), amiodarone was associated with a neutral survival in CHF/STAT and improvement in survival in GESICA. In patients with nonsustained ventricular tachycardia, the MADIT trial demonstrated that therapy with an implantable cardioverter‐defibrillator (ICD) improved survival compared with the antiarrhythmic drug arm in such patients, most of whom were taking amiodarone. In sustained VT/VF patients, the CASCADE trial demonstrated that empiric amiodarone lowered arrhythmic recurrence rates compared with other drugs guided by serial Holter or electrophysiologic studies. Several trials including AVID, CIDS, and CASH have demonstrated the superiority of ICD therapy compared with empiric amiodarone in improving overall survival. Clinical implications of these trials are discussed.

Keywords: amiodarone, clinical trials, ventricular tachycardia

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Reference

  • 1. Gilman JK, Jalal S, Naccarelli GV: Predicting and preventing sudden death from cardiac causes. Circulation 1994; 90: 1083–1092 [DOI] [PubMed] [Google Scholar]
  • 2. Teo KK, Yusuf S, Furberg CD: Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: An overview of results from randomized controlled trials. J Am Med Assoc 1993; 270: 1589–1595 [PubMed] [Google Scholar]
  • 3. Lau J, Antman EM, Jimenez Silva J, Kupelnic B, Mosteller F, Chalmers TC: Cumulative meta‐analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248–254 [DOI] [PubMed] [Google Scholar]
  • 4. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J: B‐blockers and sudden cardiac death. Ann Intern Med 1995; 123: 358–367 [DOI] [PubMed] [Google Scholar]
  • 5. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE: Adjunctive drug therapy of acute myocardial infarction—evidence from clinical trials. N Engl J Med 1996; 335: 1660–1667 [DOI] [PubMed] [Google Scholar]
  • 6. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel BJ, Russell RO, Smith EE, Weaver WD: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28: 1328–1428 [DOI] [PubMed] [Google Scholar]
  • 7. Naccarelli GV, Wolbrette DL, Dell'Orfano JT, Patel HM, Luck JC: A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: From CAST to AVID and beyond. J Cardiovasc Electrophysiol 1998; 9: 864–891 [DOI] [PubMed] [Google Scholar]
  • 8. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias Manno D, Barker AH, Arensberg D, Baker A, Friedman PL, Greene HL, Huther ML, Richardson DW, and the CAST Investigators : Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781–788 [DOI] [PubMed] [Google Scholar]
  • 9. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP: Effect of d‐sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996: 348: 7–12 [DOI] [PubMed] [Google Scholar]
  • 10. Impact Research Group : International mexiletine and placebo antiarrhythmic coronary trial I. Report on arrhythmia and other findings. J Am Coll Cardiol 1984; 4: 1148–1163 [DOI] [PubMed] [Google Scholar]
  • 11. Julian DG, Prescott RJ, Jackson FS, Szekely P: Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982; 1: 1142–1147 [DOI] [PubMed] [Google Scholar]
  • 12. The Cardiac Arrhythmia Suppression Trial II Investigators : Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227–233 [DOI] [PubMed] [Google Scholar]
  • 13. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D: Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990; 16: 1711–1718 [DOI] [PubMed] [Google Scholar]
  • 14. Pfisterer ME, Kiowski W, Brunner H, Burckhardt D, Burkart F: Long‐term benefit of 1 year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. Circulation 1993; 87: 309–311 [DOI] [PubMed] [Google Scholar]
  • 15. Ceremuzynski L, Kleczar E, Krzeminska Pakula M, Kuch J, Nartowicz E, Smielak Korombel J, Dyduszynski A, Maciejewewicz J, Zaleska T, Lazarczyk Kedzia E, Motyka J, Paczkowska B, Sczaniecka O, Yusuf S: Effect of amiodarone on mortality after myocardial infarction: A double‐blind placebo‐controlled, pilot study. J Am Coll Cardiol 1992; 20: 1056–1062 [DOI] [PubMed] [Google Scholar]
  • 16. Navarro Lopez F, Cosin J, Marrugat J, Guindo J, Bayes de Luna A, for the SSSD Investigators : Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. Am J Cardiol 1993; 72: 1243–1248 [DOI] [PubMed] [Google Scholar]
  • 17. Julian DG, Camm AJ, Franglin G, Janse MJ, Munoz A, Schwartz PJ, Simon P, for the European Myocardial Infarct Amiodarone Trial Investigators : Randomized trial of effect of amiodarone on mortality in patients with left‐ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667–674 [DOI] [PubMed] [Google Scholar]
  • 18. Cairns JA, Connolly SJ, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators : Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349: 675–682 [DOI] [PubMed] [Google Scholar]
  • 19. Sim I, McDonald KM, Lavori PW, Norbutas CM, Hlatky MA: Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997; 96: 2823–2829 [DOI] [PubMed] [Google Scholar]
  • 20. Amiodarone Trials Meta‐Analysis Investigators : Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta‐analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350: 14317–1424 [PubMed] [Google Scholar]
  • 21. Ho K, Pinsky J, Kannel W, Levy D: The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993; 22: 6A–13A [DOI] [PubMed] [Google Scholar]
  • 22. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527–532 [DOI] [PubMed] [Google Scholar]
  • 23. Stevenson WG, Stevenson LW, Middlekauff HR, Fonarow GC, Hamilton MA, Woo MA, Saxon LA, Natterson PD, Steimle A, Walden JA, Tillisch JH: Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996; 28: 1458–1463 [DOI] [PubMed] [Google Scholar]
  • 24. Cleland JGF, Dargie HJ, Findlay JN, Wilson JT: Clinical hemodynamic and antiarrhythmic effects of long‐term treatment with amiodarone of patients in heart failure. Br Heart J 1987; 57: 436–445 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Cleland JGF, Dargie HJ, Ford I: Mortality in heart failure: Clinical variables of prognostic value. Br Heart J 1987; 58: 572–582 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Nicklas JM, McKenna WJ, Stewart RA, Mickelson JK, Das SK, Schork MA, Krikler SJ, Quain LA, Morady F, Pitt B: Prospective double‐blind, placebo‐controlled trial of low‐dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991; 122: 1016–1021 [DOI] [PubMed] [Google Scholar]
  • 27. Garguichevich JJ, Ramos JL, Gambarte A, Gentile A, Hauad S, Scapin O, Sirena J, Tibaldi M, Toplikar J: Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine pilot study of sudden death and amiodarone (EPAMSA). Am Heart J 1995; 130: 494–500 [DOI] [PubMed] [Google Scholar]
  • 28. Doval HC, Nul DR, Grancelli HO, Perrone SV, Borman GR, Curiel R for Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) : Randomized Trial of Low‐Dose Amiodarone in Severe Congestive Heart Failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344: 493–498 [DOI] [PubMed] [Google Scholar]
  • 29. Doval HC, Nul DR, Grancelli HO, Varini SD, Soifer S, Corrado G, Dubner S, Scapin O, Perrone SV, for the GESICA‐GEMA Investigators : Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. Circulation 1996; 94: 3198–3203 [DOI] [PubMed] [Google Scholar]
  • 30. Nul DR, Doval HC, Grancelli HO, Varini SD, Soifer S, Perrone SV, Prieto N, Scapin O, on behalf of the GESICA‐GEMA Investigators : Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol 1997; 29: 1199–1205 [DOI] [PubMed] [Google Scholar]
  • 31. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure (CHF‐STAT) : Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia (CHF‐STAT). N Engl J Med 1995; 333: 77–82 [DOI] [PubMed] [Google Scholar]
  • 32. Singh SN, Fisher SG, Carson PE, Fletcher RD, for the CHF STAT Investigators : Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. J Am Coll Cardiol 1998; 32: 942–947 [DOI] [PubMed] [Google Scholar]
  • 33. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN, for the Department of Veterans Affairs CHF‐STAT Investigators : Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observations for the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF‐STAT). Circulation 1998; 98: 2574–2579 [DOI] [PubMed] [Google Scholar]
  • 34. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials : Overview of randomized trials of angiotensin‐converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J Am Med Assoc 1995; 273: 1450–1456 [PubMed] [Google Scholar]
  • 35. Nisam S, Mower M: ICD trials: An extraordinary means of determining patient risk? PACE 1998; 21: 1341–1346 [DOI] [PubMed] [Google Scholar]
  • 36. Bigger JT, Fleiss JL, Kleiger R, Miller JP, Rolnitsky LM, Multicenter Post‐Infarction Research Group : The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the two years after myocardial infarction. Circulation 1984; 69: 250–258 [DOI] [PubMed] [Google Scholar]
  • 37. Wilber DJ, Olshansky B, Moran JF, Scanlon PJ: Electrophysiological testing and nonsustained ventricular tachycardia. Use and limitations in patients with coronary artery disease and impaired ventricular function. Circulation 1990; 82: 350–358 [DOI] [PubMed] [Google Scholar]
  • 38. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M, for the Multicenter Automatic Defibrillator Implantation Trial Investigators : Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933–1940 [DOI] [PubMed] [Google Scholar]
  • 39. Buxton AE, Fisher JD, Josephson ME, Lee K, Pryor DB, Prystowsky EN, Simson MB, DiCarlo L, Echt DS, Packer D, Greer GS, Talajic M, The MUSTT Investigators : Prevention of sudden death in patients with coronary artery disease: The Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis 1993; 36: 215–226 [DOI] [PubMed] [Google Scholar]
  • 40. Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R, Zou KH, Moss AJ: Cost‐effectiveness of automatic implantable cardiac defibrillators: Results from MADIT. Circulation 1998; 97: 2129–2135 [DOI] [PubMed] [Google Scholar]
  • 41. Buxton AE, Lee KL, DiCarlo L, Echt DS, Fisher JD, Greer GS, Josephson ME, Packer D, Prystowsky EN, Talajic M, for the Multicenter Unsustained Trial (MUSTT) Investigators : Nonsustained ventricular tachycardia in coronary artery disease: Relation to inducible sustained ventricular tachycardia. Ann Intern Med 1996; 125: 35–39 [DOI] [PubMed] [Google Scholar]
  • 42. The CASCADE Investigators : Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993; 72: 280–287 [DOI] [PubMed] [Google Scholar]
  • 43. Siebels J, Cappato R, Ruppel R, Schneider MAE, Kuck KH, and the CASH Investigators : Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am J Cardiol 1993; 72: 109F–113F [DOI] [PubMed] [Google Scholar]
  • 44. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators : A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near‐fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576–1583 [DOI] [PubMed] [Google Scholar]
  • 45. Curtis AB, Hallstrom AF, Klein RC, Nath S, Pinski SL, Epstein AE, Wyse DG, Cannom DS, Renfroe E, for the AVID Investigators : Influence of patient characteristics in the selection of patients for defibrillator implantation (the AVID Registry). Am J Cardiol 1997; 79: 1185–1189 [DOI] [PubMed] [Google Scholar]
  • 46. Kim SG, Hallstrom A, Love JC, Rosenberg Y, Powell J, Roth J, Brodsky M, Moore R, Wilkoff B, for the AVID Investigators : Comparison of clinical characteristics and frequency of implantable defibrillator use between randomized patients in the Antiarrhythmics Vs. Implantable Defibrillators (AVID) trial and nonrandomized registry patients. Am J Cardiol 1997; 80: 454–457 [DOI] [PubMed] [Google Scholar]
  • 47. Anderson JL, Hallstrom AP, Epstein AE, Pinski SL, Rosenberg Y, Nora MO, Chilson D, Cannom DS, Moore R, and the AVID Investigators : Design and results of the Antiarrhythmics vs. Implantable Defibrillators (AVID) registry. Circulation 1999; 99: 1692–1699 [DOI] [PubMed] [Google Scholar]
  • 48. Connolly S, Gent M, Roberts R, Dorian P, Green MS, Klein GJ, Mitchell LB, Sheldon RS, Roy D: Canadian Implantable Defibrillator Study (CIDS): Study design and organization. Am J Cardiol 1993; 72: 103F–108F [DOI] [PubMed] [Google Scholar]
  • 49. Wever EFD, Hauer RNW, van Capelle FJL, Tijssen JGP, Crijns HJGM, Algra A, Wiesfeld ACP, Bakker PFA, Robles de Medina EO: Randomized study of implantable defibrillator as first‐choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation 1995; 91: 2195–2203 [DOI] [PubMed] [Google Scholar]
  • 50. Naccarelli GV, Fineberg NS, Zipes DP, Heger JJ, Duncan G, Prystowsky EN: Amiodarone: Risk factors for recurrence of symptomatic ventricular tachycardia identified at electrophysiologic study. J Am Coll Cardiol 1985; 6: 814–821 [DOI] [PubMed] [Google Scholar]
  • 51. Myerburg RJ, Mitrani R, Interian A, Castellanos A: Interpretation of outcomes of antiarrhythmic clinical trials. Design features and population impact. Circulation 1998; 97: 1514–1521 [DOI] [PubMed] [Google Scholar]
  • 52. Bigger JT, for the CABG Patch Trial Investigators : Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997; 337: 1569–1575 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES